These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 17541852)

  • 61. Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.
    Lett TA; Walter H; Brandl EJ
    CNS Drugs; 2016 Dec; 30(12):1169-1189. PubMed ID: 27752945
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Impact of Antidepressant Drugs on Sexual Function and Satisfaction.
    Baldwin DS; Manson C; Nowak M
    CNS Drugs; 2015 Nov; 29(11):905-13. PubMed ID: 26519341
    [TBL] [Abstract][Full Text] [Related]  

  • 63. CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression.
    Han KM; Chang HS; Choi IK; Ham BJ; Lee MS
    Psychiatry Investig; 2013 Sep; 10(3):286-93. PubMed ID: 24302953
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants.
    Baldwin DS; Palazzo MC; Masdrakis VG
    Depress Res Treat; 2013; 2013():256841. PubMed ID: 23431429
    [TBL] [Abstract][Full Text] [Related]  

  • 65. P-glycoprotein (PGP) polymorphisms and sexual dysfunction in female patients with depression and SSRI-associated sexual side effects.
    Bly MJ; Bishop JR; Thomas KL; Ellingrod VL
    J Sex Marital Ther; 2013; 39(3):280-8. PubMed ID: 23356581
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pharmacokinetics of venlafaxine extended release 75  mg and desvenlafaxine 50  mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.
    Nichols AI; Focht K; Jiang Q; Preskorn SH; Kane CP
    Clin Drug Investig; 2011; 31(3):155-67. PubMed ID: 21288052
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.
    Lash TL; Pedersen L; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Hamilton-Dutoit S; Garne JP; Ewertz M; Sørensen HT
    Br J Cancer; 2008 Aug; 99(4):616-21. PubMed ID: 18665165
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects.
    Zourková A; Hadasová E
    Gen Physiol Biophys; 2003 Mar; 22(1):103-13. PubMed ID: 12870705
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Relationship between CYP 2D6 metabolic status and sexual dysfunction in paroxetine treatment.
    Zourková A; Hadasová E
    J Sex Marital Ther; 2002; 28(5):451-61. PubMed ID: 12378847
    [TBL] [Abstract][Full Text] [Related]  

  • 70. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
    Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G
    Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity.
    Zourková A; Cesková E; Hadasová E; Ravcuková B
    J Sex Marital Ther; 2007; 33(4):343-55. PubMed ID: 17541852
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
    Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A
    Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacokinetics, drug interactions, and tolerability of paroxetine and paroxetine CR.
    DeVane CL
    Psychopharmacol Bull; 2003; 37 Suppl 1():29-41. PubMed ID: 14566199
    [TBL] [Abstract][Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.